POINT Biopharma Ownership
| PNTDelisted Stock | USD 9.06 0.10 1.09% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
POINT |
POINT Stock Ownership Analysis
About 15.0% of the company outstanding shares are owned by corporate insiders. The book value of POINT Biopharma was at this time reported as 4.01. The company had not issued any dividends in recent years. POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana. Point Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. To find out more about POINT Biopharma Global contact Joe McCann at 647 812 2417 or learn more at https://www.pointbiopharma.com.POINT Biopharma Global Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific POINT Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on POINT Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases POINT Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bvf Partners L P over six months ago Sale by Bvf Partners L P of 8974245 shares of POINT Biopharma | ||
Joe McCann over a year ago POINT Biopharma exotic insider transaction detected | ||
Bvf Partners L P over a year ago POINT Biopharma exotic insider transaction detected | ||
Fleshner Neil E over a year ago Bona fide gift to Fleshner Neil E of 250000 shares of POINT Biopharma subject to Section 16 | ||
Martell Bridget A over a year ago Acquisition by Martell Bridget A of 80503 shares of POINT Biopharma subject to Rule 16b-3 | ||
Goodman Jonathan R over a year ago Acquisition by Goodman Jonathan R of 44749 shares of POINT Biopharma subject to Rule 16b-3 | ||
Demers William L over a year ago Acquisition by Demers William L of 131355 shares of POINT Biopharma subject to Rule 16b-3 | ||
Hogue Gerald L over a year ago Exercise or conversion by Hogue Gerald L of 17936 shares of POINT Biopharma subject to Rule 16b-3 |
POINT Biopharma Outstanding Bonds
POINT Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. POINT Biopharma Global uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most POINT bonds can be classified according to their maturity, which is the date when POINT Biopharma Global has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in POINT Stock
If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |